Stock Events

Stock Events

Fennec Pharmaceuticals 

€5.5
11
+€0.05+0.92% Thursday 19:55

Statistics

Day High
5.5
Day Low
5.25
52W High
8.2
52W Low
4.3
Volume
-
Avg. Volume
-
Mkt Cap
154.34M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.3
-0.21
-0.12
-0.03
Expected EPS
-0.0391497586531344
Actual EPS
N/A

Financials

-0.86%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
90.13MRevenue
-776,194.49Net Income

Analyst Ratings

$13.66Average Price Target
The highest estimate is 13.66.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RV41.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with Fennec Pharmaceuticals in the oncology sector, particularly in developing treatments for cancer-related conditions.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a leading pharmaceutical company that develops cancer therapies, directly competing with Fennec Pharmaceuticals' focus on oncology.
Novartis
NVS
Mkt Cap237.61B
Novartis AG competes in the pharmaceutical industry by offering a wide range of oncology drugs, which puts it in direct competition with Fennec Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops and markets oncology drugs, competing with Fennec Pharmaceuticals in the cancer treatment space.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in the discovery, development, and marketing of cancer drugs, making it a competitor to Fennec Pharmaceuticals in the oncology field.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG, with its strong portfolio in oncology, competes with Fennec Pharmaceuticals in developing and marketing cancer treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a significant presence in the oncology sector, developing treatments that compete with Fennec Pharmaceuticals' cancer-focused therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its innovative therapies in oncology, among other areas, competing with Fennec Pharmaceuticals in the cancer treatment market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in competition with Fennec Pharmaceuticals in the development of cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is involved in the development of oncology drugs, competing with Fennec Pharmaceuticals in the cancer therapy market.

About

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Show more...
CEO
Mr. Rostislav Raykov
Employees
36
Country
CA
ISIN
CA31447P1009
WKN
000A12A5F

Listings

F
DE
RV41.F
BOATS
BOATS
FENC.BOATS
XNAS
US
FENC
TO
CA
FRX.TO

0 Comments

Share your thoughts

FAQ

What is Fennec Pharmaceuticals stock price today?▼
The current price of RV41.F is €5.5 EUR — it has increased by +0.92% in the past 24 hours. Watch Fennec Pharmaceuticals stock price performance more closely on the chart.
What is Fennec Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Fennec Pharmaceuticals stocks are traded under the ticker RV41.F.
Is Fennec Pharmaceuticals stock price growing?▼
RV41.F stock has risen by +14.58% compared to the previous week, the month change is a -18.52% fall, over the last year Fennec Pharmaceuticals has showed a +2.8% increase.
What is Fennec Pharmaceuticals market cap?▼
Today Fennec Pharmaceuticals has the market capitalization of 154.34M
When is the next Fennec Pharmaceuticals earnings date?▼
Fennec Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Fennec Pharmaceuticals earnings last quarter?▼
RV41.F earnings for the last quarter are -0.02 EUR per share, whereas the estimation was -0.02 EUR resulting in a +8.72% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Fennec Pharmaceuticals revenue for the last year?▼
Fennec Pharmaceuticals revenue for the last year amounts to 90.13M EUR.
What is Fennec Pharmaceuticals net income for the last year?▼
RV41.F net income for the last year is -776,194.49 EUR.
How many employees does Fennec Pharmaceuticals have?▼
As of April 03, 2026, the company has 36 employees.
In which sector is Fennec Pharmaceuticals located?▼
Fennec Pharmaceuticals operates in the Health Care sector.
When did Fennec Pharmaceuticals complete a stock split?▼
The last stock split for Fennec Pharmaceuticals was on September 05, 2014 with a ratio of 1:3.
Where is Fennec Pharmaceuticals headquartered?▼
Fennec Pharmaceuticals is headquartered in Research Triangle Park, CA.